Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 2051 - 2075 of 15153 in total

Quazepam

Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABAA receptors and low affinity for...
Approved
Illicit
Matched Description: … It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. ... in its relatively high affinity for sleep-promoting α1 subunit-containing GABAA receptors and …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepine hypnotics and sedatives ... Benzodiazepines and benzodiazepine derivatives …

1,2-Distearoyllecithin

Approved
Experimental

Zoledronate D,L-Lysine Monohydrate

Approved
Investigational
Matched Iupac: … 2,6-diaminohexanoic acid [1-hydroxy-2-(1H-imidazol-1-yl)-1-phosphonoethyl]phosphonic acid hydrate …

Lisuride

An ergot derivative that acts as an agonist at dopamine D2 receptors (dopamine agonists). It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (serotonin agonists).
Approved
Investigational
Matched Description: … It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors …
Matched Categories: … Ergot Alkaloids and Derivatives ... Genito Urinary System and Sex Hormones …

Dronedarone

Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate control, rhythm control, prevention...
Approved
Matched Description: … toxicities, such as thyroid and pulmonary toxicities. ... calcium ion channels and inhibiting β-adrenergic receptors. ... It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of …

Ivabradine

Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus...
Approved
Matched Description: … is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and ... Although non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart ... pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and …
Matched Categories: … metoprolol and ivabradine ... carvedilol and ivabradine …

Alosetron

Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. Alosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer...
Approved
Withdrawn
Matched Description: … reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured bowel, and ... Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal …
Matched Categories: … Alimentary Tract and Metabolism …

Ammonia N-13

Ammonia N 13 Injection, USP is a positron emitting radiopharmaceutical that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging. The active ingredient, [13N] ammonia, has the molecular formula of 13NH3 with a molecular weight of 16.02. Ammonia N 13 Injection, USP is used for imaging...
Approved

Ferrous cysteine glycinate

Approved
Matched Iupac: … lambda2-iron(2+) (2R)-2-amino-3-sulfanylpropanoic acid 2-aminoacetic acid (2R)-2-amino-3-sulfanidylpropanoate …

Mepivacaine

A local anesthetic that is chemically related to bupivacaine but pharmacologically related to lidocaine. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168)
Approved
Vet approved
Matched Description: … It is indicated for infiltration, nerve block, and epidural anesthesia. ... Mepivacaine is effective topically only in large doses and therefore should not be used by this route …
Matched Mixtures name: … Mepivacaine Hydrochloride and Levonordefrin …

Lanreotide

Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured by the company, Ipsen...
Approved
Matched Description: … It is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. ... Lanreotide is manufactured by the company, _Ipsen Pharmaceuticals_ as lanreotide acetate, and marketed …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Somatostatin and Analogues ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Velmanase alfa

Velmanase alfa is a recombinant human lysosomal alpha-mannosidase developed for enzyme replacement therapy to treat alpha-mannosidosis. Alpha-mannosidosis is a rare autosomal recessive lysosomal storage disorder. Patients with alpha-mannosidosis have a genetic mutation that causes a deficiency in the lysosomal enzyme alpha-mannosidase, which is an enzyme responsible for breaking down complex...
Approved
Investigational
Matched Description: … Velmanase alfa has an amino acid sequence of the monomeric protein identical to the naturally occurring ... deterioration, such as skeletal abnormalities, motor function impairment, intellectual disability, and ... sugars in the body leads to an array of clinical manifestations leading to progressive neuromuscular and …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …

Tadalafil

Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy.[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibitors...
Approved
Investigational
Matched Description: … that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and ... [L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. ... In contrast to other PDE5 inhibitors like [sildenafil], tadalafil has greater selectivity for PDE5 and …
Matched Categories: … tamsulosin and tadalafil ... macitentan and tadalafil ... ambrisentan and tadalafil ... finasteride and tadalafil ... Genito Urinary System and Sex Hormones …

Conivaptan

Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2).
Approved
Investigational
Matched Description: … Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). …

Phenyl aminosalicylate

Approved

Chloramphenicol palmitate

Approved
Vet approved

Selpercatinib

Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including cabozantinib, ponatinib, sorafenib, sunitinib, and vandetanib, have shown efficacy in RET-driven cancers, their...
Approved
Investigational
Matched Description: … Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and ... Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Insulin degludec

Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the...
Approved
Matched Description: … A18563,A18564,A174934] Compared to endogenous insulin, insulin degludec has an added hexadecanedioic acid ... tissues such as the liver, fat cells, and skeletal muscle. ... inhibits lipolysis and proteolysis among many other functions. …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... insulin degludec and liraglutide ... insulin degludec and insulin aspart ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Sodium glycerophosphate

Sodium glycerophosphate is one of several glycerophosphate salts. It is used clinically to treat or prevent low phosphate levels [FDA Label]. Glycerophosphate is hydrolyzed to inorganic phosphate and glycerol in the body . The extent of this reaction is dependent on the activity of serum alkaline phosphatases.
Approved
Matched Description: … Glycerophosphate is hydrolyzed to inorganic phosphate and glycerol in the body [A32667]. …
Matched Mixtures name: … Vitamin and Mineral Supplement - Liq ... Hemarexin Liquid and Drinkable Ampoules …
Matched Categories: … Blood and Blood Forming Organs ... Blood Substitutes and Perfusion Solutions …

Tafasitamab

Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies. It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytotoxicity relative to non-engineered anti-CD19...
Approved
Investigational
Matched Description: … an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytotoxicity ... results in the lysis of B-cells (both healthy and malignant). ... [L15302] It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Chloramphenicol succinate

Chloramphenicol succinate is an ester prodrug of chloramphenicol. Chloramphenicol is a bacteriostatic antibiotic. Use of chloramphenicol succinate and chloramphenicol has decreased due to the risk of potentially fatal blood dyscrasias. Chloramphenicol succinate was granted FDA approval on 20 February 1959.
Approved
Matched Iupac: … 4-[(2R,3R)-2-(2,2-dichloroacetamido)-3-hydroxy-3-(4-nitrophenyl)propoxy]-4-oxobutanoic acid …
Matched Description: … [A204065] Use of chloramphenicol succinate and chloramphenicol has decreased due to the risk of potentially …

Raltegravir

Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Approved
Matched Description: … Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase …
Matched Categories: … lamivudine and raltegravir …

Dolutegravir

Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity. Dolutegravir was developed by ViiV Healthcare...
Approved
Matched Description: … [A31342] Dolutegravir was developed by ViiV Healthcare and FDA-approved on August 12, 2013. ... The effect of this drug has no homology in human host cells, which gives it excellent tolerability and …
Matched Categories: … lamivudine and dolutegravir ... dolutegravir and rilpivirine ... lamivudine, abacavir and dolutegravir ... lamivudine, tenofovir disoproxil and dolutegravir …

Alpelisib

Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target...
Approved
Investigational
Matched Description: … Alpelisib is marketed under the trade name Piqray and is available as oral tablets. ... that plays a role in various biological processes, including proliferation, survival, differentiation, and ... To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Cyclandelate

A direct-acting smooth muscle relaxant used to dilate blood vessels. It may cause gastrointestinal distress and tachycardia. Cyclandelate is not approved for use in the U.S. or Canada, but is approved in various European countries.
Approved
Matched Description: … It may cause gastrointestinal distress and tachycardia. …
Displaying drugs 2051 - 2075 of 15153 in total